Examining a Text Message Intervention for Smoking Cessation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- The Miriam Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 35
- Current daily smoker
- Has a cell phone with text messaging capability
- Uses text messaging at least once monthly
- Interested in quitting smoking
- Willing to set a quit date within the next 30 days
- Has access to a physician
Exclusion Criteria:
- Does not read and speak English with adequate comprehension
- Is currently participating in a smoking cessation program
- Concurrent drug/alcohol abuse
- Mental health issues that would interfere with study compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Text Messaging
A text message-based intervention for smoking cessation
|
A 7-week program of daily text messages
|
|
Placebo Comparator: Control
Individuals in this group will receive generic (non-smoking related) text messages on the same schedule as the intervention arm.
This provides a control for staff/program contact time and participant burden.
|
non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Smoking abstinence
Time Frame: Six months post-treatment
|
7-day point prevalence abstinence will be measured at 6 months post-treatment.
|
Six months post-treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Usability and Acceptability of the intervention
Time Frame: 7 weeks (end of treatment)
|
Usability and acceptability of the intervention will be assessed at the end of treatment (week 7).
|
7 weeks (end of treatment)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Beth C Bock, PhD, The Miriam Hospital, Brown Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- R21DA027142 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.